Bicara Therapeutics has appointed Jeremy Bender and Christy Oliger to its board of directors. Dr. Bender most recently served as CEO of Day One Biopharmaceuticals through its approximately $2.5 billion acquisition by Servier in 2026, and brings more than 20 years of biotech corporate strategy and operating experience. Ms. Oliger brings more than 30 years of commercial and operating experience, having most recently served as Senior Vice President of the Oncology Business Unit at Genentech, where she managed a portfolio of 15 products contributing U.S. revenue exceeding $13 billion. The company also announced that founding board member Kiran Mazumdar-Shaw has retired from the board.
Bicara Therapeutics Inc. Common StockAppointment of experienced board members with strong biotech and commercial backgrounds strengthens governance and strategic oversight.